Abstracts - faqs.org

Abstracts

Retail industry

Search abstracts:
Abstracts » Retail industry

Who's to say they will never recover?

Article Abstract:

Long-term coma patients, known as in a persistent vegetative state (PVS), may recover after three years or longer, but there is only one rehabilitation unit in the UK, in Putney, London. Ordinary hospitals do not know where to place them so when they arrive at the rehabilitation unit they are usually undernourished and have muscular contractures. A coma arousal programme stimulates the patient through touch, smell and taste. About half regain consciousness but will be physically and mentally disabled.

Author: Hunt, Liz
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1992
Care and treatment, United Kingdom, Hospitals, Buildings and facilities, Coma, Coma (Medicine), Rehabilitation centers, Persistent vegetative state

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Must they beg for the price of a better life?

Article Abstract:

Multiple sclerosis, a chronic degenerative condition of the nervous system for which there is currently no cure, affects 85,000 people in the UK. The condition is being treated in the US with the drug Beta-Interferon, and promising results have been reported. It has not yet been licensed in the UK, but can be prescribed with the approval of a consultant under the 'named patient' scheme for new drugs. However, most GPs are reluctant to prescribe it because it is very expensive.

Author: Hunt, Liz
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1995
Multiple sclerosis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Atishoo! Atishoo! They all cash in

Article Abstract:

Scientists have not yet been successful in developing a reliable way of curing influenza, so any new product in this area still attracts considerable attention. One of the lastest products is Glaxo Wellcome's GG167 compound, which is now to be the subject of large-scale clinical trials as numbers of influenza cases rise dramatically. This product could become available as a nasal spray or inhallation from as early as 1997.

Author: Hunt, Liz
Publisher: Financial Times Ltd.
Publication Name: The Independent
Subject: Retail industry
ISSN: 0951-9467
Year: 1995
Column, Influenza

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Drug therapy
Similar abstracts:
  • Abstracts: Let's not change into the Bull Ring. How far would you go for the sake of a child? Alders, apples and wild brown trout
  • Abstracts: The Virgin who just wants to be loved. It may be Corsa, but is it any better? Executive Tart works to rule
  • Abstracts: Who's there to help when things go wrong? Testing times after the boycott. Meet my professor, the movie star
  • Abstracts: Why would a miner strike in 1995? The battle for George Michael. When hell burst through the pavement and grew
  • Abstracts: Waiting for Waitrose to come to town. Built for the people - so tell the people
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.